Intellia Therapeutics, Inc. (NTLA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Intellia Therapeutics, Inc. (NTLA)
Go deeper and ask any question about NTLA
Company Performance
Current Price
as of Sep 13, 2024$22.07
P/E Ratio
N/A
Market Cap
$2.24B
Description
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerNTLA
- Price$22.07+6.77%
Trading Information
- Market Cap$2.24B
- Float98.23%
- Average Daily Volume (1m)1,171,220
- Average Daily Volume (3m)1,486,197
- EPS-$5.48
Company
- Revenue$45.97M
- Rev Growth (1yr)-48.82%
- Net Income-$146.98M
- Gross Margin62.64%
- EBITDA Margin-1,961.25%
- EBITDA-$136.44M
- EV$1.59B
- EV/Revenue34.49
- P/EN/A
- P/S46.56